Medicinal cannabis company Zelira Therapeutics (ASX:ZLD) says its Phase 1 Dose Escalation Trial in patients on long-term opioid treatment is now fully enrolled.
"No serious adverse events from dosing patients have been reported to date. Dosing is expected to be completed by April 2020 with the final report to be provided by mid 2020," it said.
The trial is evaluating the safety and tolerability of whole plant extract following single and repeated doses with escalation in patients with chronic non-cancer pain on long-term opioid analgesia. Secondary outcomes include pharmacokinetics and the effects on pain, mood, sleep and opioid use over the duration of the trial.
The trial is being undertaken at the St Vincent’s Hospital in Melbourne in conjunction with Emerald Clinics (ASX:EMD) in Perth.
“We are delighted to have achieved full enrolment, which represents a major milestone for the trial. We’re also pleased for the opportunity to expand our partnership with Emerald Clinics by bringing them on as a second site. We have been impressed by their ability to complement the efforts of the St Vincent team by rapidly screening and enrolling eligible patients into trial," said Zelira managing director Dr Richard Hopkins.